Britain and America have forged a significant bilateral deal that will preserve zero import taxes on British pharmaceutical products entering the US market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to raise spending on medicines through the public health system. This pledge guarantees that duties on these crucial goods will stay at nothing for a timeframe of the next three years.
This deal follows recent warnings to dramatically increase import taxes on branded drug imports, with potential rates discussed as high as 100%.
"This arrangement with the UK reinforces the global environment for new treatments and brings long-overdue equity to American-British medicine commerce," an announcement said.
Commercial Significance
Medicines are one of the the United Kingdom's biggest export categories to the America, which is clearly the biggest market for large UK drugmakers.
Trade data reveal that in the one-year period prior to September, the UK sold drugs totaling £11.1bn to the US. This amount represented 17.4% of all goods exports in that period.
"This deal protects employment, boosts funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a government official remarked.
Key British Pledges
The deal includes several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at 15%. Previously, refunds exceeded 20%.
Industry Background
The pact takes place against a ongoing tension between the sector and the British authorities over spending levels and approval rates.
These tensions were intensified by claims that US customers were charged significantly more for the equivalent treatments than patients in the other developed nations.
Recently, several large manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar funding commitments have been directed toward American operations.
One official acknowledged that the NHS had to spend more on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the last ten years.
